Neuroendocrine tumors (NETs) result from the abnormal growth of neoplasms that originate from cells of various endocrine glands and nervous systems. Though most of these are benign, some tend to become malignant and may turn cancerous in the long term. Neuroendocrine tumors are generally infected initially in intestine, which are often known as carcinoid tumors. Pancreas is the second most prime organ in the body, where growth of NET is common. There are number of clinical trials are ongoing to develop the novel therapy or drugs for the treatment of the pancreatic neuroendocrine tumors in adult patients.
Market Dynamics
The rising incidence of GI and lung neuroendocrine tumors is a key factor that is expected to fuel growth of the global neuroendocrine tumor treatment market over the forecast period. For instance, according to data published in American Society of Clinical Oncology (ASCO) in 2019, estimated 12,000 people in the U.S. are diagnosed with a NET, each year. And around 170,000 people are living currently with NET. The 5-year survival for NET of the small intestine was 86.2%, 82.7% for stomach, and 67.4% for colon. Apart from GI and Lung Neuroendocrine, there are other factors, which influence NET include hormonal imbalance at pituitsary gland and thyroid gland. The rising demand for various imagining techniques in North America and Europe is expected to fuel growth of the global market over the forecast period. Drug portfolio expansion and development of new products that can inhibit excess hormone production are some of the other factors that are expected to augment growth of the global neuroendocrine tumor treatment market over the forecast period.
Key features of the study:
- This report provides in-depth analysis of the neuroendocrine tumor treatment market, market size (US$ Million) and Compound Annual Growth Rate (CAGR (%)) for the forecast period, 2019 – 2027, considering 2018 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global neuroendocrine tumor treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
- Key companies covered as a part of this study include Pfizer Inc, Novartis AG, Ispen, Advanced Accelerator Applications, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc., and Exelixis, Inc.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, end user upgrades, market expansion, and marketing tactics
- The global neuroendocrine tumor treatment market report caters to various stakeholders in this industry, including investors, drug/product manufacturers, distributors and suppliers for neuroendocrine tumor treatment market, research and consulting firms, new entrants, and financial analysts
- Various strategy matrices used in analyzing the neuroendocrine tumor treatment market would provide stakeholders vital inputs to make strategic decisions accordingly
Detailed Segmentation:
- Global Neuroendocrine Tumor Treatment Market, By Treatment Type :
- Somatostatin Analogues (SSAs)
- Octreotide
- Lanreotide
- Others
- Targeted Therapy
- Chemotherapy
- Others
- Global Neuroendocrine Tumor Treatment Market, By Indication:
- Gastrointestinal NET
- Lung NET
- Pancreatic NET
- Other NET
- Global Neuroendocrine Tumor Treatment Market, By End User:
- Hospitals
- Oncology Centers
- Others
- Global Neuroendocrine Tumor Treatment Market, By Region:
- North America
- By Treatment Type:
- Somatostatin Analogues (SSAs)
- Octreotide
- Lanreotide
- Others
- Targeted Therapy
- Chemotherapy
- Others
- By Indication:
- Gastrointestinal NET
- Lung NET
- Pancreatic NET
- Other NET
- By End User
- Hospitals
- Oncology Centers
- Others
- By Country:
- Europe
- By Treatment Type:
- Somatostatin Analogues (SSAs)
- Octreotide
- Lanreotide
- Others
- Targeted Therapy
- Chemotherapy
- Others
- By Indication:
- Gastrointestinal NET
- Lung NET
- Pancreatic NET
- Other NET
- By End User
- Hospitals
- Oncology Centers
- Others
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Treatment Type:
- Somatostatin Analogues (SSAs)
- Octreotide
- Lanreotide
- Others
- Targeted Therapy
- Chemotherapy
- Others
- By Indication:
- Gastrointestinal NET
- Lung NET
- Pancreatic NET
- Other NET
- By End User
- Hospitals
- Oncology Centers
- Others
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Latin America
- By Treatment Type:
- Somatostatin Analogues (SSAs)
- Octreotide
- Lanreotide
- Others
- Targeted Therapy
- Chemotherapy
- Others
- By Indication:
- Gastrointestinal NET
- Lung NET
- Pancreatic NET
- Other NET
- By End User
- Hospitals
- Oncology Centers
- Others
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- By Treatment Type:
- Somatostatin Analogues (SSAs)
- Octreotide
- Lanreotide
- Others
- Targeted Therapy
- Chemotherapy
- Others
- By Indication:
- Gastrointestinal NET
- Lung NET
- Pancreatic NET
- Other NET
- By End User
- Hospitals
- Oncology Centers
- Others
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Treatment Type:
- Somatostatin Analogues (SSAs)
- Octreotide
- Lanreotide
- Others
- Targeted Therapy
- Chemotherapy
- Others
- By Indication:
- Gastrointestinal NET
- Lung NET
- Pancreatic NET
- Other NET
- By End User
- Hospitals
- Oncology Centers
- Others
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Pfizer Inc*
- Company Overview
- Drug Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Future Plans
- Novartis AG
- Ispen
- Advanced Accelerator Applications
- Tarveda Therapeutics
- Progenics Pharmaceuticals, Inc.
- Hutchison Medipharma Limited
- Dauntless Pharmaceuticals Inc.
- Exelixis, Inc.
“*” marked represents similar segmentation in other categories in the respective section
